An increase suggests the company is accounting for future restructuring costs without immediate cash impact, potentially signaling efficiency initiatives.
This metric captures the portion of restructuring expenses that were recognized in the income statement but did not resu...
Varies significantly based on the company's current phase of operational transformation or cost-cutting programs.
other_restructuring_reserve_settled_without_cash2| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | $0.00 | $0.00 | $6.00M | $8.00M | $0.00 | $0.00 | $11.00M | -$19.00M |
| Prescription Technology Solutions | $1.00M | $1.00M | $0.00 | $7.00M | $0.00 | $0.00 | $0.00 | $17.00M |
| North American Pharmaceutical | — | — | — | $14.50M | — | — | -$3.00M | $14.00M |
| International | $1.00M | — | — | — | $0.00 | — | — | — |
| U.S. Pharmaceutical | $1.00M | $63.00M | $1.00M | — | $0.00 | — | — | — |
| Total | — | — | — | — | — | — | — | — |
Oncology & Multispecialty is derived from annual filings.
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.